Janssen Biotech, a unit of New Brunswick-based Johnson & Johnson, has partnered with China-based Legend Biotech USA and Legend Biotech Ireland to collaborate on a new cancer drug, LCAR-B38M, which is meant to be used in conjunction with CAR T cell cancer therapy.
CAR T cell therapy is a new, immunological treatment for sufferers of a rare form of cancer called multiple myeloma, which was usually a death sentence. In November, Hackensack Meridian Health’s John Theurer Cancer Center became the first New Jersey-based medical facility in the state to offer the life-saving treatment after engaging in a research partnership with New York’s Memorial Sloan Kettering Cancer Center.
The new drug targets the B-cell maturation antigen, thus helping to improve a patient’s immune system to better target and attack cancer cells associated with multiple myeloma. The new drug has been accepted for review by the China Food and Drug Administration and has been approved for the planning phase of clinical studies by the U.S. Food and Drug Administration.
"Despite significant advances, multiple myeloma remains an incurable disease for most patients, creating the need for additional, highly active options. LCAR-B38M provides an innovative approach with the potential to transform the treatment of myeloma," said Dr. Peter Lebowitz, global therapeutic area head, Oncology at Janssen Research & Development, in a press release.